Telomir's Telomir-1 Shows Promise in Reducing Intracellular Iron

On November 12, 2025, Telomir Pharmaceuticals unveiled new preclinical findings demonstrating Telomir-1's efficacy in lowering intracellular iron in human keratinocytes. The investigational compound outperformed Deferoxamine (DFO), the current FDA-approved standard, indicating its potential for better cell penetration and iron modulation.

The study, using FerroOrange, showed significant iron reduction over DFO, implying Telomir-1’s robust intracellular performance. This aligns with Telomir's exploration of metal-ion imbalance impacts on oxidative stress and disease progression.

Telomir-1's unique formulation with zinc aims to balance metal ions, enhancing cellular function. It provides a distinct approach compared to DFO, with potential for fewer side effects. Telomir continues preclinical evaluations to further understand Telomir-1’s cellular and enzymatic impacts.